血清CEA水平对EGFR-TKI治疗的非小细胞肺癌患者预后的评估价值

The Value of Serum CEA Level in Evaluating the Prognosis of Patients with Non-small Cell Lung Cancer Treated with EGFR-TKI

目的:探讨血清癌胚抗原(CEA)水平对表皮生长因子受体酪氨酸激酶受体抑制剂(EGFRTKI)治疗的非小细胞肺癌患者预后的评估价值。方法:选择2017年1月-2018年4月在本院进行EGFR-TKI治疗的非小细胞肺癌患者68例的资料进行回顾性分析。在患者接受EGFR-TKI治疗之前的1个月均对其血清的CEA水平进行检查,按照血清CEA浓度是否高于5.0 ng/mL分为血清CEA正常组38例与血清CEA升高组30例。比较两组生存情况,筛选EGFR-TKI治疗非小细胞肺癌患者预后的影响因素。结果:血清CEA正常组无进展生存时间和总生存时间均高于血清CEA升高组,差异均有统计学意义(P<0.05);年龄≥60岁、吸烟、TNM分期高、血清CEA水平≥5.0 ng/mL是影响EGFR-TKI治疗非小细胞肺癌患者预后的独立因素(P<0.05)。结论:血清CEA水平增高的非小细胞肺癌患者使用EGFR-TKI治疗的预后较差,血清CEA水平可以作为该类患者预后评估的指标,但还需要进行大规模试验的验证。

Objective:To investigate the value of serum carcinoembryonic antigen(CEA)level in the prognosis of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase receptor inhibitor(EGFR-TKI).Method:The data of 68 patients with non-small cell lung cancer who received EGFR-TKI treatment in our hospital from January 2017 to April 2018 were retrospectively analyzed.CEA levels in serum were measured 1 month before patients were treated with EGFR-TKI,according to whether the serum CEA concentration was higher than 5.0 ng/mL,they were divided into the 38 cases of serum CEA normal group and 30 cases of serum CEA elevation group.The survival of the two groups was compared,the factors influencing the prognosis of patients with non-small cell lung cancer treated with EGFR-TKI were screened.Result:The progression-free survival time and total survival time of patients in the serum CEA normal group were higher than those in the serum CEA elevation group,the differences were statistically significant(P<0.05).The age of patients≥60 years old,smoking,high TNM stage,and serum CEA level≥5.0 ng/mL were independent factors affecting the prognosis of patients with non-small cell lung cancer treated with EGFR-TKI(P<0.05).Conclusion:Patients with non-small cell lung cancer with elevated serum CEA have a poor prognosis when treated with EGFR-TKI.Serum CEA level can be used as an indicator of prognosis in these patients,but large-scale trials are still needed to verify this.